GLP1R and familial dilated cardiomyopathy: Additionally, while drugs like SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated benefits in improving cardiac function and glucose metabolism in patients with DCM (107, 108, 111, 113), their side effects present significant limitations in clinical practice.